

# This is an overview about all ongoing clinical trials of the CCCA and the cooperating network partners.

To find the right contact person, please orientate yourself here at the respective study and the named study site. >><u>Detailed contact information can then be found at 'ISCO | Contact Information'.</u>

Skin Cancer		
Indication	Study	Study site
Melanoma	<b>NIVO-PASS</b> Pattern of use and safety/effectiveness of Nivolumab in routine oncology practice.	UKA Dept. of Dermatology
Melanoma	<b>NIS-NICO</b> A national, prospective, non-interventional study (NIS) of Nivolumab monotherapy or in combination with Ipilimumab in patients with advanced melanoma and in Patients with adjuvant Nivolumab therapy.	UKA Dept. of Dermatology
Melanom Stad. II	<b>NivoMela</b> Adjuvant Nivolumab Treatment of Stage II Melanoma at High Risk of Recurrence. A randomized, controlled, phase III clinical trial with biomarker-based risk stratification	UKA Dept. of Dermatology
Malignant melanoma	ADOREG Nationwide prospective registry for health services research in dermatologic oncology Indication: maliganant melanoma from stage IIB, epithelial skin tumors, actinic keratosis.	UKA Dept. of Dermatology
Advanced, metastasized melanoma	IO102-IO103-013 (IOB-013) A phase 3, open-label, randomized, clinical trial of IO102-IO103 in combination with Pembrolizumab versus Pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma.	UKA Dept. of Dermatology
completely resected high-risk Melanoma	<b>R3767-ONC-2055</b> A Phase 3 Trail of Fianlimab (Anti-LAG-3) and Cemiplimab versus Pembrolizumab in the adjuvant setting in patients with completely resected high-risk Melanoma	UKA Dept. of Dermatology



BRAFV600-mutated melanoma	Bering Melanoma Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi- national, prospective, longitudinal, non- interentional study in Germany and Austria.	UKA Dept. of Dermatology
CSCC	<b>CemiSkin</b> Registry study with two cohorts for patients with advanced CSCC treated with Cemiplimab or other approaches.	UKA Dept. of Dermatology
Merkel cell carcinoma	<b>MCC-Trim</b> Noninterventional cohort registry study to assess characteristics and management of patients with merkel cell carcinoma in Germany.	UKA Dept. of Dermatology
Basal cell carcinoma, cutaneous squamous cell carcinoma	Philogen PH-L19IL2TNFNMSC-04/19 Patients with locally advanced (non- metastatic, node-negative, single or multifocal) basal cell carcinoma (BCC) or high-risk cutaneous squamous cell carcinoma (cSCC) who are suitable for intratumoral injection, who are not eligible for surgery or radiotherapy based on the assessment of a local multidisciplinary tumor board, or who decline surgery or radiotherapy, and for whom histologic assessment is available according to international guidelines. A phase II study of intratumoral administration of L19IL2/L19TNF in patients with non- melanoma skin cancer who have injectable lesions.	UKA Dept. of Dermatology



Gastrointestinal Cancer/Liver and Pancreatic Cancer		
Indication	Study	Study site
Early gastrointestinal carcinomas	ESD Register Germany: Early carcinomas of the GI tract	UKA Dept. of Internal Medicine III
	Endoscopic submucosal dissection of early gastrointestinal tract carcinomas.	
Colon carcinoma	CIRCULATE	UKA Dept. of Internal
	Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217.	Medicine III
Adenoma colon	CURE	UKA Dept. of Internal
	FTR vs. conventional endoscopic therapy for recurrent or incompletely resected non- lifting colorectal adenomas.	Medicine III
Colon, papilla, barret	KI-Colon/Papille/Barrett	UKA Dept. of Internal
Early carcinomas	Endoscopic detection of early stages of carcinoma using computer-aided diagnosis (CAD) with AI algorithms.	Medicine III
Colon cancer	AAV-AH 01	UKA Dept. of Internal
and/or renal cell cancer	Ex vivo identification of specific gene vector capsids for tumor-targeted gene therapy with adeno-associated viral vectors.	Medicine II
Colorectal carcinoma	BNT000-001	Hematological oncological
	Epidemiological study to determine the prevelence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up.	practice Heinrich, M.D./Bangerter, M.D.
Colorectal carcinoma	ColoPredict Plus 2.0 Register	Medical center Ostallgäu-
	Retro and prosepctive evaluation of the role of MSI and KRAS regarding the prognosis of patients with stage I-III colorectal carcinoma.	Kaufbeuren Medical center Aichach- Friedberg
Colorectal carcinoma	Supportive care trial evaluating the prevalence of malnutrition in centralized care of patients with colorectal carcinoma.	Medical center Ostallgäu- Kaufbeuren

Update: 27.01.2024




CRC, metastasized	FIRE8 Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of Trifluridine/Tipiracil plus Panitumumab versus Trifluridine/Tipiracil plus Bevacizumab as first-line treatment of metastatic colorectal cancer.	UKA Dept. of Internal Medicine II
ССС/НСС	Jade Clinical research platform on treatment and outcome in patients with hepatocellular or cholangiocellular cancer.	UKA Dept. of Internal Medicine II
Metastatic gastrointestinal cancer	<b>GOBLET</b> A phase 1 / 2 multiple - indication biomarker, safety, and efficacy study in advanced of metastatic gastrointestinal cancers exploring treatment combinations with Pelareorep and a Tezolizumab.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Gastric carcinoma, colorectal carcinoma	<b>Triangle SARIFA</b> Prospective investigation of the SARIFA phenomenon as a prognostic biomarker in patients with colorectal carcinoma or gastric carcinoma	UKA Dept. of Internal Medicine II
Pankreatic cancer, distal bile duct cancer, papillary cancer	<b>PORRIDGE</b> A prospective randomized study comparing intraoperative endoluminal pyloromyotomy with atraumatic pyloric dilatation in the setting of pylorus- preserving duodenohemipancreatectomy	Dept. of General, Visceral and Transplant Surgery
	in terms of incidence and severity of postoperative delayed gastric emptying.	
CCC		UKA Dept. of Internal Medicine II



AEG	RAMIRIS	UKA Dept. of Internal
	Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic	Medicine III
	adenocarcinoma of the stomach or gastro- esophageal junction, who failed one prior line of palliative chemotherapy.	
	Hematological Neoplasms	
Indication	Study	Study site
ALL	GMALL-Registry and biomaterial bank	UKA Dept. of Internal
	Biomaterial collection and prospective data collection on diagnosis, treatment and disease progression of adult ALL.	Medicine II
ALL	GMALL-EVOLVE	UKA Dept. of Internal
	A multicentre, randomized trial in adults with de novo PhiladelphiaChromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with Blinatumomab and chemotherapy in optimal responders and to evaluate Blinatumomab before SCT in suboptimal responders	Medicine II
AML	<b>AML register and biomaterial database</b> of the Study Alliance Leukemia (SAL) and the AML Cooperative Group (AML-CG).	UKA Dept. of Internal Medicine II
AML	<b>VR-MEDITATE</b> Relaxation exercises in virtual reality.	UKA Dept. of Internal Medicine II
AML	<b>DECIDER-2</b> Prospective randomized multicenter phase III trial of Decitabine and Venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.	UKA Dept. of Internal Medicine II


## CCCA | Clinical Trials Overview






AML MDS	PALOMA Primary compArison of LiposOmal Anthracycline based treatment versus conventional care strategies before allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML – the PALOMA study, phase III.	UKA Dept. of Internal Medicine II
AML, MDS, CMML, MPN (BCR/ABL1- negativ), BPDCN	BMS CA055-001 A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Oral-Aza, Onureg) in Subjects with Moderate or Severe Hepatic Impairment Compared with Normal Hepatic Function in Adult Subjects with Myeloid Malignancies	UKA Dept. of Internal Medicine II
CLL	CLL2-BZAG A prospective, open-label, multicenter phase - II trial to evaluate the efficacy and safety of a sequential regimen of Bendamustin followed by Obinutuzumab (GA101), Zanubritinib (BFB-3111) and Venetoclax (ABT-199).	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
CLL	<b>BO43243</b> A phase IB open-label, multicenter study evaluating the safety, efiicacy, and pharmacokinetics of Mosunetuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.	UKA Dept. of Internal Medicine II
CML	ASC4START (CABL001J12302) A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral Asciminib versus Nilotinib in patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.	UKA Dept. of Internal Medicine II
CML	BlastCrisis Register Multicentric prospective and retrospective register study, collecting patient with CML blast crisis diagnosed in Germany and Europe.	UKA Dept. of Internal Medicine II

## CCCA | Clinical Trials Overview






DLBCL	DALY 2 EU	UKA Dept. of Internal
	A pivotal Phase II randomised, multi- centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.	Medicine II
DLBCL	<b>ARCHED/GLA 2022-1</b> A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R- miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma	UKA Dept. of Internal Medicine II
Relapsed aggressive lymphoma	<b>GOAL II</b> A prospective, multicenter randomized phase II trial investigating Gemcitabine / Oxaliplatin / Rituximab with or without Mor208 for patients with relapsed /refractory aggressive lymphoma.	UKA Dept. of Internal Medicine II
Non-Hodgkin Lymphoma	<b>CHARLY</b> Phase-II study on the value of post- transplant cyclophosphamide after haplo- identical stem cell transplantation for poor- risk non-Hodgkin lymphoma (CHARLY Trial).	UKA Dept. of Internal Medicine II
MDS	SELECT-MDS-1 A Randomized, Double-blind, Placebo- controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher- risk Myelodysplastic Syndrome <b>Protocol</b> Number: SY-1425-301	UKA Dept. of Internal Medicine II
Multiple myeloma	AlloRelapseMM Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after first-line therapy.	UKA Dept. of Internal Medicine II





Multiple myeloma	<b>GMMG-HD8/DSMM XIX</b> A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma	UKA Dept. of Internal Medicine II
Myeloid neoplasms	<b>GSG-MPN-Registerstudy</b> German MPN-Registry for BCR-ABL1- negative myeloid neoplasms.	UKA Dept. of Internal Medicine II
Myelofibrosis	<b>TRANSFORM-2</b> Randomized, open-label, phase 3 trial comparing the efficacy and safety of Navitoclax in combination with Ruxolitinib against standard therapy in relapsed/refractory myelofibrosis.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
PCNSL	<b>OptiMATe</b> Optimizing MATRix as remission induction in PCNSL: deescalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III Trial.	UKA Dept. of Internal Medicine II
PCNSL	<b>PRIMA-CNS</b> Age-adjusted high-dose chemotherapy followed by Auto-SCT or conventional chemotherapy with R-MP as first-line treatment in elderly CNS lymphoma patients – a randomized phase III trial	UKA Dept. of Internal Medicine II
GcHD-Prophylaxis after alloHSZT	<b>GRAPPA</b> " <u>Gra</u> ft vs Host Disease <u>P</u> rophylaxis in unrelated donor transplantation: a randomized clinical trial comparing <u>P</u> TCY vs <u>A</u> TG" (GRAPPA).	UKA Dept. of Internal Medicine II
Allogeneic transplant patients	<b>PHOEBUS (MPOH08)</b> A multi-center randomized, double blind phase IIb trial evaluating oral pooled fecal microbiotherapie MaaT033 to prevent allogenetic hematopoietic cell transplantation complications	UKA Dept. of Internal Medicine II
Head and Neck Cancer		
Indication	Study	Study site

### CCCA | Clinical Trials Overview



C./

UNIVERSITÄTSKLINIKUM AUGSBURG

Comprehensive Cancer Center Augsburg

Update: 27.01.2024

Parotideal tumors	Study to evaluate the incidence of parotideal tumors and current therapeutic options.	Dept. of Otorhinolaryngology
Sinunasal squamous cell carcinoma	SentiNose Pilot A prospective study to evaluate the safety and feasibility of sentinel lymph node biopsy for sinunasal squamous cell carcinoma without clinical lymph node metastasis.	UKA Dept. of Otorhinolaryngology

Lung and Thoracic Cancer		
Indication	Study	Study site
NSCLC	<b>Beamion LUNG (BI 1479-0001)</b> An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations.	UKA Dept. of Internal Medicine II
NSCLC metastatic to the brain	<b>Break B5</b> A prospective phase II, open-label, multi- center trial of combined Nivolumab, Ipilimumab and Bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain.	UKA Dept. of Internal Medicine II
NSCLC oligometastatic	<b>BZKF sOMD</b> Biomarker analysis in patients with non- small cell lung cancer at the stage of oligometastasis at the time of initial diagnosis.	UKA Dept. of Internal Medicine II
	Breast and Gynecological Cancer	
Indication	Study	Study site
Breast Cancer (adjuvant/palliativ)	<b>Praegnant</b> Prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/metastatic setting; health care research, pharmacogenomics, biomarkers, health economics.	Dept. of Gynecology and Obstetrics



Breast cancer (adjuvant)	Tropion-Breast 03 A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION- Breast03)	Dept. of Gynecology and Obstetrics
Breast cancer (neoadjuvant)	<b>TRIO-048</b> An Open-Label, Randomized, Non- Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2– Breast Cancer in the Neoadjuvant Setting	Dept. of Gynecology and Obstetrics
Breast cancer (neoadjuvant)	Olympia N A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2-Negative Breat Cancer (OlympiaN)	Dept. of Gynecology and Obstetrics
Breast cancer advanced/metastatic	<b>CAPTOR</b> Comprehensive analysis of spation, temporal and molecular patterns of Ribociclib efficiacy and resistance in advanced breast cancer patients	Dept. of Gynecology and Obstetrics
Breast cancer advanced/metastatic	MINVERA Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management. The MINERVA Trial - A phase IV Trial	Dept. of Gynecology and Obstetrics



Breast cancer	SerMa: Prospective, interventional, multicenter non-AMG/MPG study to detect possible markers for prediction of cancer risk and risk assessment of a breast seroma after skin-sparing mastectomy and implant breast reconstruction.	Dept. of Gynecology and Obstetrics
Breast cancer	WAVES Mutual patient-doctor exchange in breast cancer care with the aim of jointly developing new patient-oriented structures.	Dept. of Gynecology and Obstetrics
Breast cancer	Astefania: A phase III, randomized, double blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant Atezolizumab or placebo and Trastuzumab Emtansine for HER2-positive breast cancer at high risk of recurrence following preoperative therapy.	Dept. of Gynecology and Obstetrics
Breast cancer	AXSANA (Axillary Surgery After NeoAdjuvant Treatment) rospective, multicenter registry study evaluating different guideline- compliant surgical procedures in the axilla (sentinel node biopsy, targeted axillary dissection, axillary dissection) after neoadjuvant chemotherapy.	Dept. of Gynecology and Obstetrics
Breast cancer	EUBREAST-01Omission of sentinel lymph node biopsy in triple-negative and HER2- positive breast cancer patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy: a single-arm, prospective surgical trial.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D. Dept. of Gynecology and Obstetrics
Breast cancer	<b>NeoMono</b> An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab - CTX therapy with Atezolizumab - CTX therapy.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.



Breast cancer	DESTINY	Hematological oncological
	A phase 3, multicenter, randomized, open- label, active-controlled study of Trastuzumab Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in subjects with high-risk Her2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes follwing neoadjuvant therapy.	practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	ADAPTIate A randomized, controlled, open-label, phase-III trial on adjuvant dynamic marker - adjusted personalized therapy. Comparsion of the combination of Abemaciclib plus standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+ / HER2- early breast cancer.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	SASCIA Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	<b>BrandO-Bio</b> Registry trial evaluating the biologic disease profile and the clinical course in breast and ovarial cancer patients.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer Detectable ESR1 Mutation	SERENA-6: A Phase III, double - blind, randomised study to assess. Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6. Inhibitor (Palbociclib or Abemaciclib) vs continuing aromatase Inhibitor. (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC. Patients with detectable ESR1 mutation without disease progression. During 1L treatment with AI + CDK4/6 Inhibitor.	Dept. of Gynecology and Obstetrics
Breast cancer	<b>OMCAT</b> Development of an artificial intelligence- based incident prediction algorithm to improve cancer patient care and patient safety	Dept. of Gynecology and Obstetrics



Breast Cancer	PRISMA	Dept. of Gynecology and
	Primary hormone-sensitive breast cancer: optimizing care on demand through a patient-centered, digital application	Obstetrics
Breast cancer (palliativ)	PreCycle	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
	Therapy with Palbociclib and Letrozole or Palbociclib and Fulvestrant.	
Breast cancer	OLIGOMA	Dept. of Gynecology and Obstetrics
	Randomized, multinational, multicenter testing of the effectiveness and tolerability of ocalradiotherapy of metastases as a supplement to standard therapy in patients with oligometastatic breast cancer.	
Endometrial cancer	ECLAT:	Dept. of Gynecology and Obstetrics
	Pelvic and paraaortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence. A multicenter prospective randomized controlled trial.	
Ovarian cancer	CAROLIN:	Dept. Of Gynecology and Obstetrics
	Characteristics related to assessments of disease, patient and treatment associated with long-term survival in ovarian cancer patients (CAROLIN) - Intergroup study NOGGO / A-AGO.	
Ovarian cancer	SCOUT-1	Dept. Of Gynecology and
	Prospective non-interventional observational study to collect clinical and patient-reported data from the daily routine of patients with ovarian cancer eligible for platinum-based first-line chemotherapy and scheduled for BCRA/HRD testing.	Obstetrics
Vulvar	DelVIN	Dept. of Gynecology and
intraepithelial neoplasia	A multicenter phase I trial evaluating the safety and preliminary efficacy of local Decitabine treatment of human papillomavirus (HPV)-induced vulvar intraepithelial neoplasia (VIN) grade 2/3.	Obestrics

#### CCCA | Clinical Trials Overview Update: 27.01.2024



Sarcoma				
Indication	Study	Study site		
Osteosarcoma	<b>COSS - Register</b> Clinical registry for children, adolescents, and adults with osteosarcoma and biologically related bone tumors of the cooperative osteosarcoma study group.	UKA Dept. of Internal Medicine II		
Urogenital Cancer				
Prostata cancer	IMPROVE Studie: Importance of various supportive measures in the context of radical prostatectomy from the patient's perspective	UKA Dept. of Urology		
	Prospective questionnaire study to evaluate the importance of various supportive measures in the context of radical prostatectomy from the patient's perspective.			
Prostata cancer	PCO Studie: Prostate Cancer Outcomes Study	UKA Dept. of Urology		
	The "Prostate Cancer Outcome" aims to contribute to improving the physical and mental health of men being treated for localised prostate cancer.			
Prostata cancer	<b>TRITON3</b> A multicenter, randomized, open-label phase 3 Study of Rucaparib versus physician's choice of therapy for patients with metastatic castration-resistant prostata cancer associated with homologous recombination deficiency.	Hematological oncological practice Heinrich, M.D./ Bangerter, M.D.		
Prostata cancer	ADAM	UKA Dept. of Urology		
	A randomized, open-label, Phase 2 Study of adjuvant Apalutamide or standard of care in subjects with high-risk, localized or locally advanced prostate cancer after radical prostatectom			
Renal cell cancer	<b>CARAT-Register</b> Prospective presentation of the cross- sectoral treatment reality for patients with locally advanced, inoperable or metastatic renal cell carcinoma	UKA Dept. of Internal Medicine II		



Renal cell cancer	AAV-AH 01	UKA Dept. of Internal
and/or Colon cancer	Ex vivo identification of specific gene vector capsids for tumor-targeted gene therapy with adeno-associated viral vectors	Medicine II
Renal cell carcinoma	CarboCare	UKA Dept. of Urology
	Prospective non-interventional study of Cabozantinib as monotherapiy or in combination with Nivolumab in patients with advanced or metastatic renal cell carcinoma, under real-life clinical setting in 1St line treatment.	
Urothelial cancer	Avenue	UKA Dept. of Urology
	Avelumab in real-world treatment of urothelial cancer – The AVENUE NIS	
	CNS-Tumors	
Glioblastoma	Intrago II	UKA Dept. of Radiotherapy
	A multicenter randomized phase III trial on Intraoperative Radiotherapy in newly diagnosed Glioblastoma multiforme (INTRAGO II)	
	Other Clinical Trials	
Metastatic solid tumors	ALPS Augsburg Longitudinal Plasma Study (ALPS) for the evaluation of Liquid Biopsy (LBx) as a tool for diagnostic support, detection of disease progression and for the identification of mutations in treatment settings of patients receiving palliative systemic treatment for solid neoplasia. Non-interventional study.	UKA Dept. of Internal Medicine II
NSCLC (neoadjuvant),	EARLy	UKA Dept. of Internal
SCLC (palliative), renal cell carcinoma (palliative), urothelial carcinoma (palliative)	Early analysis of response to immunotherapy using lymphocyte differentiation	Medicine II
Radionuclide therapy	ZIS RNT	
	Characterization of the cellular immune status in patients treated with radionuclide therapy	